[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infections-cytomegalovirus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infections-cytomegalovirus":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100603790","a-prospective-single-arm-observational-study-of-maribavir-for-the-treatment-of-post-hematopoietic-stem-cell-transplantation-cytomegalovirus-infection-100603790",false,"NCT07141095","A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection","Inclusion Criteria:\n\n* Hematopoietic Stem Cell Transplant Recipients\n\n  1. Adult patients with an expected survival of ≥4 weeks.\n  2. Confirmed CMV infection, including CMV viremia and CMV disease.\n  3. Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria are not eligible for this study:\n\n  1. Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.\n  2. At screening, liver function tests show: AST \\> 5×ULN, or ALT \\> 5×ULN, or total bilirubin ≥ 3.0×ULN.\n  3. Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.\n  4. Participants deemed unsuitable for inclusion by the investigator.","ALL","12 Years",{"count":18,"type":19},17,"ESTIMATED","OBSERVATIONAL","The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.\n\nThe participants will be treated with maribavir for up to 8 weeks.",[23],"Infections, Cytomegalovirus","NOT_YET_RECRUITING","2025-08-18",{"date":27,"type":28},"2025-08-26","ACTUAL",{"date":30,"type":19},"2025-09-25",{"date":32,"type":19},"2027-01-31",{"name":34,"class":35},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":36},"100520486","phase-2-efficacy-of-letermovir-in-preventing-cytomegalovirus-cmv-infection-in-lung-transplant-recipients-vs-valganciclovir-100520486","NCT06057194","Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.","Prospective Study to Assess the Efficacy of Letermovir Prophylaxis in Preventing CMV Infection in Lung Transplant Recipients Compared to a Retrospective Cohort Treated With Standard Valganciclovir Prophylaxis for 12 Months (LETERCOR Study)","LETERCOR","Inclusion Criteria (prospective cohort):\n\n* Adults over 18 years old\n* Lung transplant recipients (D+\u002FR-) pre-transplant.\n* Having an undetectable CMV polymerase chain reaction assay (PCR) within the 96 hours prior to the start of letermovir prophylaxis.\n* Patients who have provided written informed consent.\n\nExclusion Criteria (prospective cohort):\n\n* HIV-infected patients.\n* Patients with multivisceral transplant.\n* Patients unable to comply with the follow-up protocol.\n* Receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis.\n* Patients with concurrent renal and hepatic insufficiency.\n\nInclusion Criteria (retrospective cohort):\n\n* Adults over 18 years old. Lung transplant recipients (D+\u002FR-) pre-transplant.\n* Patients treated with Valganciclovir prophylaxis for 12 months.\n* Patients transplanted within 2 years prior to the start of the study.\n* Patients with a complete 13-month follow-up and comparable data to the prospective cohort to evaluate the study's primary variables.\n\nExclusion Criteria (retrospective cohort):\n\n* HIV-infected patients.\n* Patients with multivisceral transplant.","18 Years",{"count":47,"type":19},90,"INTERVENTIONAL",[50],"PHASE2","The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+\u002FR-) compared to a historical cohort of lung transplant recipients (D+\u002FR-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease.\"",[23],[54,55,56],"Lung transplant","CMV prophylaxis","Cytomegalovirus","2023-09-25",{"date":59,"type":28},"2023-09-28",{"date":61,"type":19},"2023-10",{"date":63,"type":19},"2027-04",{"name":65,"class":35},"Maimónides Biomedical Research Institute of Córdoba"]